PROLACTINOMA

✓ Medically ReviewedDISEASEID: MDBT0277🚨 TRIAGE: URGENTICD-10: D35.2

📖

Definition

CLINICAL DEFINITION

Prolactinoma is a benign, prolactin-secreting neoplasm arising from lactotroph cells of the anterior pituitary gland, representing the most common functional pituitary adenoma. It is biochemically characterised by hyperprolactinaemia and is classified by maximal tumour diameter as microadenoma (≤10 mm), macroadenoma (>10 mm), or giant adenoma (>40 mm). The diagnosis is established by the combination of elevated serum prolactin, typically in a pattern concordant with tumour size, and imaging evidence of a pituitary adenoma, after exclusion of other causes of hyperprolactinaemia including drug effects, stalk compression, and pregnancy.

IN PLAIN ENGLISH

A prolactinoma is a non-cancerous tumour of the pituitary gland that makes too much prolactin, a hormone that normally stimulates breast milk production. The extra prolactin can cause irregular periods or infertility in women, and low sex drive or erectile problems in men, and larger tumours can press on nearby structures and affect vision.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Prolactinoma is NOT synonymous with hyperprolactinaemia: most hyperprolactinaemia is not caused by a prolactinoma. Drug-induced hyperprolactinaemia, stalk compression by a non-functioning lesion (the 'stalk effect'), primary hypothyroidism, pregnancy, and renal failure are important non-adenomatous causes that must be excluded before attributing hyperprolactinaemia to a prolactinoma. Prolactinoma is also distinct from non-functioning pituitary adenomas, which do not secrete prolactin and produce hyperprolactinaemia only through stalk compression.

🔤

Word Breakdown

prolactin-

=prolactin, from 'pro-' (for, in favour of) + 'lact-' (milk) + '-in' (protein suffix), referring to the hormone that promotes lactation

-oma

=tumour or swelling (from Greek '-ōma')

Literal Meaning: A tumour of prolactin-producing cells

🏷️

Abbreviations

PRLoma=Prolactinoma — abbreviated form used in pituitary clinic documentation and consensus literature

PRL=Prolactin — the hormone secreted in excess by the adenoma; serum PRL is the primary biochemical marker

DA=Dopamine agonist — the first-line pharmacologic therapy class for prolactinoma

🔄

Synonyms & Variants

Prolactin-secreting pituitary adenoma›Lactotroph adenoma›PRL-secreting pituitary adenoma›Prolactin-secreting pituitary neuroendocrine tumour›

🎯

Category-Specific Context

Prolactinoma is a disease within the spectrum of pituitary neuroendocrine tumours (PitNETs). Clinically, it is stratified by tumour size — microadenoma (≤10 mm), macroadenoma (>10 mm), and giant adenoma (>40 mm) — because size correlates with the likelihood of mass effect, the magnitude of hyperprolactinaemia, and the probability of surgical remission. An additional dimension of severity is cavernous sinus invasion, commonly assessed by the Knosp classification on MRI, which influences surgical feasibility and remission rates.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicNeurosurgery ClinicGynaecology ClinicReproductive Endocrinology ClinicOphthalmology ClinicGeneral Medicine WardEmergency Department

USAGE & DOCUMENTATION NOTES

In clinical documentation, prolactinoma is typically recorded with tumour size and prolactin level, for example: 'Macroprolactinoma (18 mm) with serum prolactin 2,400 ng/mL.' Clinicians commonly use the abbreviated form 'PRLoma' in endocrine and neurosurgical notes. Referral letters to endocrinology usually state the prolactin value, the presence or absence of hypogonadism or visual field involvement, and current dopamine agonist therapy. In pregnancy planning, notes explicitly document the dopamine agonist used, whether it was discontinued at conception, and the plan for monitoring for tumour growth.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Prolactin secretion from anterior pituitary lactotrophs is under tonic inhibitory control by dopamine delivered via the hypothalamic–pituitary portal circulation. Dopamine binds D2 receptors on lactotrophs and suppresses both prolactin gene transcription and lactotroph proliferation. Prolactinomas are clonal lactotroph neoplasms that escape this dopaminergic inhibition, producing prolactin autonomously. The resulting hyperprolactinaemia suppresses hypothalamic kisspeptin and gonadotrophin-releasing hormone (GnRH) neurons, reducing gonadotrophin (LH and FSH) secretion and leading to hypogonadotrophic hypogonadism. In women this manifests as oligomenorrhoea or amenorrhoea, with or without galactorrhoea; in men it causes reduced libido, erectile dysfunction, and infertility. Prolactin itself directly stimulates mammary gland lactation. As the adenoma enlarges, it can compress the optic chiasm and cavernous sinus, producing visual field defects and cranial nerve palsies, and can impair secretion of other pituitary hormones by mass effect.

PRIMARY CAUSES

Sporadic lactotroph adenoma (somatic mutation)

A somatic genetic event confers a growth advantage to a single lactotroph lineage, producing a clonal neoplasm that secretes prolactin independently of dopamine inhibition; most prolactinomas are sporadic monoclonal tumours.

Multiple endocrine neoplasia type 1 (MEN1)

Germline MEN1 mutation predisposes to pituitary adenomas, of which prolactinoma is the most common functional subtype; MEN1-associated macroprolactinomas may be more aggressive and relatively resistant to dopamine agonist therapy.

Familial isolated pituitary adenoma (FIPA), including AIP mutation

AIP germline variants and other FIPA-related genetic defects can predispose to young-onset prolactinoma, which may present as a large or invasive tumour, particularly in male patients.

🌍

Epidemiology

Prevalence:Orphanet reports a prevalence of 1–5 per 10,000 in the general population, with European registry estimates of approximately 1 per 1,600–2,200 in Belgium, the UK, and Switzerland. Prolactinoma accounts for approximately 50% of all pituitary adenomas and 66% of clinically relevant pituitary adenomas. Incidence and prevalence estimates have increased over recent decades, partly reflecting more sensitive imaging and prolactin assays.

Age Group:Peak onset is in the second to fourth decades of life. Prolactinoma predominantly affects women of reproductive age (25–44 years), in whom microadenomas are most common; after menopause the sex ratio equalises. Men are more likely to present at an older age with macroadenomas. Giant prolactinomas are rare and can occur at any age, with some genetic forms (AIP, MEN1) presenting in childhood or adolescence.

Sex Predilection:Female

Geographic Distribution:No major geographic or ethnic variation in the biological occurrence of prolactinoma is established. Reported prevalence differences between regions largely reflect differences in case ascertainment, imaging access, and diagnostic coding rather than true variation in disease frequency. Orphanet notes European prevalence estimates of 1/1,600–2,200, but comparable international registry data are limited.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Sudden severe headache, visual deterioration, or cranial nerve palsy in a patient with a known prolactinoma should raise concern for pituitary apoplexy, an endocrinological emergency requiring urgent imaging and neurosurgical/endocrine assessment.
A large pituitary mass with only modestly elevated prolactin may represent the hook effect rather than a non-functioning adenoma; requesting a diluted prolactin assay avoids misclassification and inappropriate surgery.

URGENT EVALUATION TRIGGERS

Sudden-onset severe headache with visual symptoms or cranial nerve palsy (possible pituitary apoplexy)
New or progressive visual field defect or visual acuity loss
Prolactinoma in pregnancy with new neurological symptoms or visual change
Severe hyponatraemia or adrenal crisis in a patient with a large pituitary mass, suggesting hypopituitarism or apoplexy

Contraindications & Precautions

SPECIAL PRECAUTIONS

Before attributing hyperprolactinaemia to a prolactinoma
rigorously exclude drug-induced hyperprolactinaemia
pregnancy
primary hypothyroidism
renal insufficiency
and stalk compression by a non-functioning lesion.
In a patient with a large pituitary adenoma and only modestly elevated prolactin
consider the high-dose hook effect and request a diluted prolactin assay before diagnosing a non-functioning adenoma.
In premenopausal women and in men
assess for hypogonadotrophic hypogonadism and consider bone mineral density evaluation when hyperprolactinaemia has been sustained.
When dopamine agonist therapy is used
counsel about nausea
postural hypotension
and impulse-control disorders; high cumulative doses of cabergoline have been associated with valvular heart disease
and cardiac surveillance should follow local guidance for patients requiring high doses.
In pregnancy
dopamine agonists are generally discontinued at conception unless there is a history of macroadenoma with prior mass effect; if tumour growth occurs
bromocriptine or cabergoline can be restarted under specialist supervision.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Hypogonadotrophic hypogonadism — suppression of GnRH and gonadotrophins
causing amenorrhoea
infertility
reduced libido
erectile dysfunction
and low bone mineral density
Osteoporosis and fragility fracture — sustained hypogonadism reduces bone mineral density; vertebral fracture prevalence and fracture rates are increased in both women and men with prolactinoma
Visual field defects — suprasellar extension of a macroadenoma compresses the optic chiasm
classically producing bitemporal hemianopia
Pituitary apoplexy — acute haemorrhage or infarction within the adenoma
presenting as sudden severe headache
visual deterioration
and endocrine dysfunction; an endocrinological emergency
Hypopituitarism — mass effect or surgical/radiation treatment can impair secretion of GH
TSH
ACTH
and other anterior pituitary hormones
Cerebrospinal fluid leak — can occur with invasive macroadenomas or after transsphenoidal surgery

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Prolactin

The hormone is prolactin; the tumour is prolactinoma. Documentation that refers only to 'prolactin' may omit the adenoma diagnosis, while 'prolactinoma' may be incorrectly recorded when the patient has hyperprolactinaemia from another cause.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Drug-induced hyperprolactinaemia

Key Distinguishing Feature: Temporal relationship to initiation or dose escalation of a dopamine D2 receptor antagonist (antipsychotic, metoclopramide, some antidepressants); prolactin typically falls after drug withdrawal or switch, and no pituitary adenoma is seen on MRI.

Stalk-effect hyperprolactinaemia

Key Distinguishing Feature: Prolactin elevation is usually modest (generally less than approximately five to six times the upper limit of normal) despite a large pituitary or parasellar mass; the tumour itself is non-functioning and hyperprolactinaemia results from interrupted dopamine delivery, not lactotroph secretion.

Primary hypothyroidism

Key Distinguishing Feature: Elevated TSH with low free T4; hyperprolactinaemia is reversible with levothyroxine replacement, and no prolactin-secreting adenoma is present.

Macroprolactinaemia

Key Distinguishing Feature: Prolactin is bound to immunoglobulin (usually IgG), producing elevated measured prolactin without true bioactive hyperprolactinaemia; polyethylene glycol precipitation or gel filtration confirms macroprolactin, and clinical features of prolactin excess are typically absent.

Pregnancy and lactation

Key Distinguishing Feature: Physiological hyperprolactinaemia with a compatible history; imaging is not indicated for hyperprolactinaemia in an otherwise healthy pregnant or lactating woman without additional features suggesting a mass lesion.

💎

Clinical Pearls

💎

Prolactinoma is the most common functioning pituitary adenoma, but the differential of hyperprolactinaemia is broad; the diagnosis requires both biochemical confirmation and imaging evidence of an adenoma, after excluding drugs, stalk effect, pregnancy, and hypothyroidism.

💎

In a patient with a macroadenoma and a prolactin level that seems inappropriately low for the tumour size, the hook effect should be excluded by requesting a diluted assay before concluding the lesion is non-functioning.

💎

Cabergoline is preferred over bromocriptine for most patients because of greater efficacy in normalising prolactin and shrinking the tumour, but bromocriptine has more extensive pregnancy safety data and is often preferred when fertility treatment requires a dopamine agonist to continue through conception.

💎

Microprolactinomas rarely enlarge, and asymptomatic microadenomas may be observed without immediate dopamine agonist therapy; treatment decisions should be guided by symptoms, hypogonadal consequences, and patient preferences rather than tumour size alone.

💎

Long-standing hypogonadism, rather than hyperprolactinaemia itself, is the principal driver of bone loss; assessment and treatment of gonadal deficiency is a key component of long-term management.

📝

Example Usage & SOAP

CLINICAL SENTENCE

""28-year-old woman with 18 months of oligomenorrhoea and galactorrhoea; serum prolactin 185 ng/mL, pituitary MRI shows a 7 mm microadenoma consistent with prolactinoma; commenced on cabergoline 0.25 mg twice weekly.""

IN A SOAP NOTE

S: 32-year-old man reports 12 months of reduced libido, erectile dysfunction, and headaches. O: Serum prolactin 1,850 ng/mL; testosterone low; pituitary MRI shows a 22 mm macroadenoma with suprasellar extension; visual fields show early bitemporal defect. A: Macroprolactinoma with hypogonadotrophic hypogonadism and early optic chiasm compression. P: Start cabergoline 0.25 mg twice weekly, titrate to prolactin; baseline echocardiogram before dose escalation; repeat visual fields and prolactin in 4–6 weeks; endocrine and neurosurgical follow-up.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for hyperprolactinaemia with a pituitary mass: (1) Prolactinoma — prolactin elevation concordant with tumour size, no stalk-compression pattern, dopamine agonist response expected. (2) Stalk-effect from a non-functioning adenoma or other parasellar mass — prolactin usually only modestly elevated despite a large mass; surgery directed at the mass rather than dopamine agonist therapy. (3) Drug-induced hyperprolactinaemia — temporal relationship to D2 antagonist, prolactin falls after withdrawal or switch. (4) Macroprolactinaemia — elevated measured prolactin without true bioactivity, confirmed by PEG precipitation. (5) Pregnancy or primary hypothyroidism — physiological or reversible causes, excluded by history, TSH, and pregnancy testing.

📊

Classifications & Scoring

GRADING SYSTEM

Knosp Classification

MRI-based grading of cavernous sinus invasion by pituitary adenomas, ranging from grade 0 (no invasion) to grade 4 (complete encirclement of the internal carotid artery). Higher Knosp grades correlate with lower surgical remission rates in prolactinoma and are used in surgical planning.

View Reference ↗

📈

Prognosis

SHORT-TERM OUTCOME

With dopamine agonist therapy, serum prolactin normalises and tumour shrinkage occurs in the majority of patients within months; gonadal function typically improves as prolactin falls. Microprolactinomas rarely enlarge, and short-term mass-effect complications are uncommon in this group. Macroprolactinomas require closer monitoring because of the potential for persistent mass effect and the slower response of larger tumours.

LONG-TERM PROGNOSIS

Microprolactinomas generally have an excellent long-term prognosis and seldom progress to macroadenomas; many can be managed with prolonged medical therapy. Long-term hypogonadism, if inadequately treated, carries a sustained risk of osteoporosis. Surgical remission rates are high for microprolactinomas but decline with larger tumour size and cavernous sinus invasion; recurrence of hyperprolactinaemia after initial surgical remission occurs in a minority. Giant and aggressive prolactinomas may require multimodal therapy and have a more guarded prognosis.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

D35.2

LITERATURE CITATIONS & GUIDELINES

[1]Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi:10.1038/s41574-023-00886-5

[2]Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.

[3]Orphanet. Prolactinoma. ORPHA:2965. Available at: https://www.orpha.net/en/disease/detail/2965

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.